The estimated Net Worth of Stacy L Taylor is at least $987 Tysiąc dollars as of 22 August 2024. Ms. Taylor owns over 26,922 units of Adaptive Biotechnologies stock worth over $611,812 and over the last 5 years she sold ADPT stock worth over $375,359. In addition, she makes $0 as Senior Vice President i General Counsel at Adaptive Biotechnologies.
Stacy has made over 27 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 26,922 units of ADPT stock worth $121,149 on 22 August 2024.
The largest trade she's ever made was selling 26,922 units of Adaptive Biotechnologies stock on 22 August 2024 worth over $121,149. On average, Stacy trades about 6,252 units every 56 days since 2020. As of 22 August 2024 she still owns at least 139,365 units of Adaptive Biotechnologies stock.
You can see the complete history of Ms. Taylor stock trades at the bottom of the page.
Stacy Taylor serves as Senior Vice President, General Counsel of the Company. Prior to joining us, Ms. Taylor served as senior associate general counsel for BTG International plc, a global specialist healthcare company, from July 2017 to March 2018. Prior to joining BTG, Ms. Taylor was a partner at the law firm of DLA Piper LLP (US) from 2007 to 2017. Ms. Taylor holds a JD from California Western School of Law and a BS in Biological Sciences, Anatomy and Physiology from California Polytechnic State University at San Luis Obispo.
Stacy Taylor is 60, she's been the Senior Vice President i General Counsel of Adaptive Biotechnologies since 2019. There are 2 older and 22 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.
Stacy's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... oraz Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies executives and other stock owners filed with the SEC include: